Description
MEXZOLE-DSR combines Esomeprazole 40 mg with Domperidone 30 mg in a sustained-release formulation. Esomeprazole reduces gastric acid production, while Domperidone helps regulate upper gastrointestinal motility and is used for nausea and vomiting in appropriate patients. This combination is documented for adult patients with gastroesophageal reflux disease (GERD) who do not respond adequately to Esomeprazole alone.
For related gastrointestinal formulations and other pharmaceutical products, explore the Medhexa Pharma capsule product range.
Therapeutic Segment
Gastrointestinal Care | GERD Management | Acid-Related Disorders | Proton Pump Inhibitors | Prokinetic Therapy
Uses of MEXZOLE-DSR
MEXZOLE-DSR may be prescribed for the management of gastroesophageal reflux disease (GERD) in adult patients who do not respond adequately to Esomeprazole alone. The combination brings together acid suppression from Esomeprazole and gastrointestinal motility support from Domperidone.
Depending on the patient’s clinical condition, a healthcare professional may consider the combination for:
- Gastroesophageal reflux disease (GERD)
- Acid reflux and associated heartburn
- Acid-related upper gastrointestinal symptoms
- GERD that remains inadequately controlled with Esomeprazole alone
- Selected gastrointestinal symptoms where the combination is considered appropriate
The exact indication, treatment duration and suitability should be determined by a healthcare professional.
Key Benefits of MEXZOLE-DSR
MEXZOLE-DSR combines two active ingredients with complementary gastrointestinal actions:
- Esomeprazole 40 mg helps reduce gastric acid secretion.
- Domperidone 30 mg SR provides a sustained-release formulation of the prokinetic component.
- The combination addresses acid suppression together with gastrointestinal motility support.
- It provides an oral capsule dosage form for convenient administration.
- The formulation is supplied in 10 × 10 ALU-ALU packaging.
The documented Indian regulatory indication specifically includes adult GERD patients who do not respond adequately to Esomeprazole alone.
How MEXZOLE-DSR Works
Esomeprazole belongs to the proton pump inhibitor (PPI) class. It suppresses gastric acid secretion by inhibiting the H⁺/K⁺-ATPase proton pump in gastric parietal cells. This reduces the amount of acid released into the stomach and helps control acid-related symptoms.
Domperidone has dopamine-receptor blocking activity and promotes upper gastrointestinal motility. It can also help control nausea and vomiting in appropriate clinical settings. However, its use requires attention to dose, duration and cardiovascular risk because of its known potential to prolong the QT interval.
Therefore, MEXZOLE-DSR combines gastric acid suppression with gastrointestinal motility support.
Common Side Effects of MEXZOLE-DSR
Some patients may experience side effects while taking Esomeprazole or Domperidone.
Possible effects include:
- Headache
- Nausea
- Abdominal discomfort
- Diarrhea
- Constipation
- Dry mouth
- Dizziness
- Flatulence
- Fatigue
Domperidone may also cause hormonal or movement-related effects in some patients.
If side effects persist, become severe or cause unusual symptoms, consult a healthcare professional.
Important Safety Information
MEXZOLE-DSR should be used only under the direction of a qualified healthcare professional.
Domperidone requires particular attention to cardiovascular safety. It has been associated with QT-interval prolongation, serious ventricular arrhythmias and, rarely, sudden cardiac death. The risk can be higher in people over 60 years of age, at higher daily doses, or when Domperidone is combined with medicines that prolong the QT interval or strongly inhibit CYP3A4.
Patients with existing QT prolongation, significant electrolyte abnormalities, bradycardia or certain underlying cardiac conditions should not use Domperidone unless specifically evaluated and advised by a healthcare professional.
Tell your healthcare professional about all medicines you take, particularly:
- Medicines known to prolong the QT interval
- Strong CYP3A4 inhibitors
- Certain anti-arrhythmic medicines
- Medicines that can affect electrolyte balance
Also inform your healthcare professional about liver or kidney problems, heart conditions, previous gastrointestinal bleeding or other significant medical conditions.
Long-term acid suppression with PPIs may require periodic medical review. Patients who need prolonged treatment should follow their healthcare professional’s monitoring advice.
Pregnant or breastfeeding patients should seek medical advice before using MEXZOLE-DSR.
For current regulatory safety information concerning Domperidone, refer to the European Medicines Agency information on Domperidone-containing medicines.
Dosage & Administration
Take MEXZOLE-DSR exactly as prescribed by your healthcare professional.
The appropriate dosage and treatment duration depend on the patient’s condition, response to treatment and the prescribing information applicable to the product.
Swallow the capsule whole with water. Do not crush, chew or open a sustained-release dosage form unless the product’s approved instructions specifically allow it.
Do not increase the dose or extend treatment without medical advice.
Because Domperidone requires careful consideration of dose and duration, use MEXZOLE-DSR only for the period recommended by the prescribing healthcare professional.
Storage
Store MEXZOLE-DSR in a cool, dry place away from excessive heat, moisture and direct sunlight.
Keep the capsules in their original ALU-ALU packaging until use.
Follow the storage conditions printed on the product packaging.
Keep out of reach of children.
